Background: The DNA-repair gene DNA-dependent kinase catalytic subunit (DNA-PKcs) favours or inhibits carcinogenesis, depending on the cancer type. Its role in human hepatocellular carcinoma (HCC) is unknown.
Human hepatocellular carcinoma (HCC) is one of the most common and lethal tumours worldwide (Villanueva et al, 2007) . Better understanding of pathogenetic mechanisms may hasten identification of new prognostic markers and development of new diagnostic and therapeutic strategies against this deadly disease (Villanueva et al, 2007; Calvisi et al, 2012) .
In recent years, we investigated the prognostic role of deregulated signalling pathways in HCC differently prone to progression, induced in rodent strains with different susceptibility to hepatocarcinogenesis, and human HCC subtypes, selected according to their clinicopathological features (Calvisi et al, 2012) . We found highest upregulation of iNOS/NF-kB (inducible nitric oxide synthase/nuclear factor-kB) and RAS/ERK (extracellular signal-regulated kinase) cascades, ubiquitination of the ERK inhibitor DUSP1 (dual-specificity phosphatase 1), and deregulation of FOXM1 (Forkhead box M1B), MYBL2 (v-Myb avian myeloblastosis viral oncogene homolog-like2; Frau et al, 2011; Calvisi et al, 2012) , and cell cycle key genes (Pascale et al, 2002 , Calvisi et al, 2012 in rapidly progressing HCC of F344 rats, genetically susceptible to hepatocarcinogenesis, and in a human HCC subtype with poorer prognosis (o3 years survival, after partial liver resection, HCCP). These changes were lower/absent in slow progressing HCC of resistant BN rats, and human HCC with better outcome (43 years survival; HCCB). Furthermore, highest ubiquitination and proteasome degradation of cell cycle inhibitors of WAF/Kip families, P130, RASSF1A (Ras-associated factor-1), and FOXO1 (forkhead box O1) contribute to cell cycle progression in F344 HCC and HCCP (Calvisi et al, 2009 ).
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) has a pivotal role in the non-homologous end-joining pathway for DNA double-strand break (DSB) repair and is required for cellular resistance to ionising radiation (Weterings and Chen, 2008; Hsu et al, 2012) . In response to DSB formation, DNA-PKcs is recruited to DSBs by the Ku70/80 heterodimer and rapidly phosphorylated at multiple serine and threonine residues (Weterings and Chen, 2008; Hsu et al, 2012) . In vivo, DNA-PKcs phosphorylation at threonine 2609 (Thr2609) is critical for DSB repair and radioresistance (Ding et al, 2003; Yajima et al, 2006; Chen et al, 2007) . In addition to its key function in DNA damage repair, DNA-PKcs has an important role in cell cycle control by orchestrating mitosis, microtubule dynamics and proper chromosomal segregation Hsu et al, 2012) . Furthermore, DNA-PKcs activity impedes the mitotic catastrophe in response to DNA damage . Based on these data, a tumour suppressor function of DNA-PKcs has been envisaged, due to its capability to safeguard the genome integrity (Hsu et al, 2012) . In accordance with this hypothesis, loss of DNA-PKcs expression was found to be a frequent event along gastric carcinogenesis, and was associated with lymphatic invasion, lymph node metastasis and poor patient survival (Lee et al, 2005) . Attenuated expression of DNA-PKcs has also been found in a subset of ovarian cancers, whereas DNA-PKcs is ubiquitously expressed in normal ovaries and in benign ovary tumours (Shao et al, 2007) . Also, reduced activity of DNA-PKcs was associated with increased risk to develop lung cancer in a population-based study (Auckley et al, 2001) . In addition, high expression of DNA-PKcs was shown to be an important predictor for better response to radiation therapy in oesophageal cancer and early breast cancer (Noguchi et al, 2002; Söderlund Leifler et al, 2010) . On the other hand, as rapidly proliferating tumour cells are exposed to various stressors, including telomere shortening, oncogene-induced DNA replication stress and generation of reactive oxidative and nitroxidative species by the tumour microenvironment, it is plausible to hypothesise that DNA-PKcs might also support carcinogenesis by protecting tumour cells from DNA damageinduced death (Hsu et al, 2012) . In accordance with the latter hypothesis, increased protein levels of DNA-PKcs have been detected in various tumour types, including colorectal, oesophageal and lung tumours, and were strongly associated with advanced clinical stages and poor survival (Hosoi et al, 2004; Tonotsuka et Xing et al, 2008) . Furthermore, increased activity of DNA-PKcs might protect cancer cells from DNA-damaging agents such as chemotherapeutic drugs and radiotherapy. Higher DNA-PKcs activity was in fact detected in glioma patients who were resistant to cisplatin-based chemotherapy (Mukherjee et al, 2009) . Also, in oral squamous cell carcinoma, a strong upregulation of DNA-PKcs and Ku proteins was detected after radiotherapy in the residual cancer cells (Shintani et al, 2003) . The latter finding suggests that induction of DNA-PKcs and Ku following radiotherapy could provide a selective survival advantage to tumour clones against radiation-induced damage and might be implicated in tumour recurrence (Shintani et al, 2003) . Thus, it has been hypothesised that inhibitors of DNA-PKcs should be highly useful in sensitising tumours to chemo-and radio-therapy as well as to prevent tumour recurrence (Shintani et al, 2003; Hsu et al, 2012) . Altogether, these observations indicate that DNA-PKcs might have paradoxically opposing roles in cancer, either favoring or inhibiting carcinogenesis, depending on the cell context or the tissue type (Hsu et al, 2012) . In HCC, a tumour type characterised by intrinsic resistance to chemotherapeutic drugs (Bruix et al, 2004) , the role of DNA-PKcs has never been investigated and remains elusive. Only one previous study suggests an oncogenic potential of DNA-PKcs in liver cancer due its ability to stabilise the c-Myc oncoprotein in the HepG2 cell line . Furthermore, the upstream regulators of DNA-PKcs in HCC and other solid tumours have been poorly defined. Here, we provide evidence that DNA-PKcs has a pro-oncogenic, pleiotropic role on HCC cells, significantly influencing their proliferation, survival and DNA-repair properties. Also, we identified the heat shock factor-1 (HSF1)/mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinase (JNK) axis as a major inducer of DNA-PKcs in HCC cells.
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MATERIALS AND METHODS
Human tissue samples. Six normal livers, 62 HCCs and corresponding surrounding non-tumour liver tissues were used. Tumours were divided in HCC with shorter/poor (HCCP; n ¼ 32) and longer/better (HCCB; n ¼ 30) survival, characterised by o3 and 43 years survival following partial liver resection, respectively (Lee et al, 2004) . Patients' features are reported in Supplementary  Table 2 . Liver tissues were kindly provided by Dr Snorri S. Thorgeirsson (National Cancer Institute, Bethesda, MD, USA) and collected at the Pietro Valdoni Surgery Department (University of Rome La Sapienza, Rome, Italy). Institutional Review Board approval was obtained at participating hospitals and the National Institutes of Health.
Proliferation and apoptotic indices, microvessel density. Proliferation and apoptotic indices were determined in human HCC by counting Ki-67-positive cells immunostained with mouse monoclonal anti-Ki67 antibody (clone MIB-1; Dako Deutschland, Hamburg, Germany) and apoptotic figures stained with the ApoTag peroxidase in situ apoptosis kit (Millipore, Billerica, MA, USA), respectively, on at least 3000 hepatocytes. Microvessel density (MVD) was evaluated in HCC slides immunostained with mouse monoclonal anti-CD34 antibody (Vector Laboratories, Burlingame, CA, USA) as previously described (Calvisi et al, 2009) . In brief, the four highest MVD areas for each tumour were photographed at high power ( Â 200) and the size of each area was standardised using the ImageJ software (http://rsb.info.nih.gov/ij/). Microvessel density was expressed as the percentage of the total CD34-stained spots per section area (0.94 mm 2 ).
Random amplified polymorphic DNA (RAPD) analysis. Twenty-two previously designed primers were used to score genomic alterations in human HCCs, and the RAPD reaction was performed as described (Luceri et al, 2000) . Differences from corresponding non-tumourous livers were scored in the case of a change in the intensity, absence of a band or appearance of a new band in HCC. The frequency of altered RAPD profiles was calculated for each liver lesion as reported (Luceri et al, 2000) .
Cell lines and treatments. The Chang and WRL-68 non-transformed liver cell lines, and the Huh6, HepG2 (harbouring wild-type p53 gene), Huh7 and Hep3B, and SNU-423 (harbouring mutated p53 gene) HCC cell lines were used for the studies in vitro. For the identification of potential HSF1-and activator protein 1 (AP-1)-binding sites in the human DNA-PKcs promoter, the TESS transcriptional element search tool was used (http:// www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=WELCOME). ChIP was performed using the ChIP Assay Kit (Millipore) following the manufacturer's protocol. The rabbit polyclonal anti-c-Jun antibody or the rabbit polyclonal anti-c-Fos (Santa Cruz Biotechnology) antibody was used to immunoprecipitate chromosomal DNA in cross-linked chromatin prepared from exponentially growing HuH6, HuH7, WRL-68, SNU-423, and HLE cell lines. Immunoprecipitated chromatin was subjected to PCR analysis using the primers DNA-PKcs Fw (TAGGGAGCGTGTGCT TCTTT) and DNA-PKcs Rv (GGGGCCTAGGTCAAGAGTTC), which produce an amplicon of 274 base pairs encompassing some of the putative AP-1-binding sites in the human DNA-PKcs promoter.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Primers for human DNA-PKcs, HSF1 and RNR18 genes were purchased from Applied Biosystems (Foster City, CA, USA). PCR reactions were performed with 100 ng of cDNA on the whole sample collection and cell lines, using an ABI Prism 7000 Sequence Detection System and TaqMan Universal PCR Master Mix (Applied Biosystems). Cycling conditions were: 10 min of denaturation at 95 1C and 40 cycles at 95 1C for 15 s and at 60 1C for 1 min. Quantitative values were calculated by using the PE Biosystems Analysis software and expressed as N target (NT). NT ¼ 2 À DCt , wherein DCt value of each sample was calculated by subtracting the average Ct value of the target gene from the average Ct value of the RNR18 gene.
Immunohistochemistry. Immunohistochemical staining was performed on 10% formalin-fixed, paraffin-embedded sections. Deparaffinised sections were incubated in 3% H 2 O 2 dissolved in PBS 1 Â for 30 min to quench the endogenous peroxidase. For antigen retrieval, slides were microwaved in 10 mM citrate buffer (pH 6.0) for 15 min. The mouse monoclonal anti-phospho-DNA-PKcs (Thr2609; Santa Cruz Biotechnology) and the rabbit polyclonal anti-phospho-HSF1 antibody (Ser326; Bioss, Woburn, MA, USA) were used at 1 : 500 and 1 : 2000 dilution, respectively. The immunoreactivity was visualised with the Vectastain Elite ABC kit (Vector Laboratories), using Vector NovaRED (Vector Laboratories) as the chromogen. Slides were counterstained with Mayer's hematoxylin. Phospho-DNA-PKcs index was determined by counting phospho-DNA-PKcs positive nuclei over 3000 hepatocyte nuclei.
DNA-PKcs and HSF1 activity assays. 
RESULTS
DNA-PKcs is upregulated in HCC. DNA-PKcs levels were assessed in human normal livers, HCCs and respective non-neoplastic surrounding livers by western blot analysis and real-time RT-PCR. A progressive upregulation of total and activated/phosphorylated (Thr2609) levels of DNA-PKcs as well as DNA-PKcs mRNA expression and activity occurred in nontumourous tissues and HCC when compared with normal livers, with the highest levels being detected in HCCP ( Figure 1A-D ). An equivalent pattern was detected when assessing the total and activated/phosphorylated levels (Ser139) of H2A histone family member X (H2AFX) protein, a DNA-PKcs downstream effector involved in DNA damage response (Fernandez-Capetillo et al, 2003; Park et al, 2003; An et al, 2010) . Subsequent immunohistochemical assessment of phosphorylated DNA-PKcs (Thr2609) showed that nuclear DNA-PKcs increased in surrounding livers and HCC with respect to normal liver (Figure 2A-I No differences occurred between surrounding liver subtypes, whereas the percentage of phosphorylated DNA-PKcs-positive nuclei was significantly higher in HCC than surrounding liver counterparts, and progressively increased from HCCB to HCCP (Figure 2A-I) .
Correlation of DNA-PKcs activity with HCC clinicopathological parameters. Next, we evaluated the relationship of DNA-PKcs activity with clinicopathological features of HCC patients. Proliferation index, genomic instability and microvessel density values positively correlated with DNA-PKcs activity, whereas the latter was inversely correlated with apoptosis ( Figure 3A-D) . Moreover, Kaplan-Meier survival curves of human HCC with high and low DNA-PKcs activity clearly showed a significant association of shorter survival with high DNA-PKcs activity ( Figure 3E ). Remarkably, in the multivariate analysis model ( Supplementary  Table 3 ), DNA-PKcs activity was significantly associated with overall survival, together with patients' sex, serum AFP level and HCC apoptosis and microvessel density.
DNA-PKcs regulates proliferation, survival and DNA-repair of HCC cells independent of p53. The role of DNA-PKcs in human liver cancer was further investigated by assessing the consequences of DNA-PKcs inactivation via siRNA in vitro. For silencing experiments, we selected two non-transformed liver cell lines, Chang and WRL-68, and four HCC cell lines: Huh6, HepG2 (harbouring wild-type p53), Huh7 and HLE (harbouring mutant p53). Specific siRNA showed an equivalent efficiency in the inhibition of DNA-PKcs in the six cell lines ( Supplementary  Figure 1) . At the cellular level, DNA-PKcs silencing reduced proliferation and induced apoptosis in the six cell lines (Figure 4) . Importantly, the effects on growth restraint were significantly higher in HCC cell lines when compared with non-transformed liver cell lines. Furthermore, when silencing of DNA-PKcs was associated with treatment with the DNA-damaging agent doxorubicin, very strong growth restraint, elevated apoptosis and massive DNA damage were detected in all HCC cell lines, irrespective of p53 status (Figure 4) . In contrast, only a slight decline in proliferation and increase in apoptosis and DNA damage was detected in Chang and WRL-68 non-transformed cell lines under the same treatment (Figure 4) . Equivalent results were obtained following administration to the cell lines of the DNA-PKcs inhibitor, NU7441 ( Supplementary Figure 2) . Altogether, the present data indicate that DNA-PKcs provides multiple growth advantages to HCC cell lines independent of p53.
HSF1 is a major inducer of DNA-PKcs in HCC cell lines.
Previous findings indicate that HSF1 has a role in the activation of DNA-PKcs (Nueda et al, 1999) , by direct interaction (Peterson et al, 1995) . Thus, we investigated this issue in HLE and HepG2 cell lines treated with doxorubicin. We found that doxorubicin treatment resulted in increased HSF1 and DNA-PKcs mRNA levels as well as HSF1-DNA-PKcs binding in HLE (Figure 5A -C) and HuH6 (not shown) cells. Heat shock transcription factor-1-DNA-PKcs binding was paralleled by increased levels of total and activated/phosphorylated DNA-PKcs (Thr2609), HSF1 (Ser326) and H2AFX (Ser139) ( Figure 5A) . Interestingly, the increase in DNA-PKcs mRNA levels following doxorubicin treatment was significantly reduced when HSF1 silencing was associated with doxorubicin administration ( Figure 5C ). The latter observation suggests a transcriptional upregulation of DNA-PKcs by HSF1. Thus, we analysed the human DNA-PKcs promoter for HSF1binding sites ( Supplementary Figure 3) . Although one putative binding site for HSF1 was identified, the subsequent ChIP experiment conducted in WRL-68, HuH6 and HLE cells failed to confirm the interaction between HSF1 and DNA-PKcs (data not shown). On the other hand, the DNA-PKcs promoter harboured several putative binding sites for AP-1, a pivotal downstream effector of MAPK and JNK pathways (Supplementary Figure 3) . The MAPK cascade has been previously shown to be a major target of HSF1 (Dai et al, 2007) . Noticeably, inhibition of either MAPK or JNK activity by U0126-or SP600125-specific inhibitors, respectively, strongly reduced the rise of DNA-PKcs mRNA induced by doxorubicin treatment in HuH6 cells ( Figure 6A ). DNA-PKcs upregulation driven by doxorubicin was further decreased when U0126 and SP600125 inhibitors were administered simultaneously. Furthermore, when HSF1 forced overexpression in SNU-423 cells was coupled to combined U0126 and SP600125 treatment, HSF1induced upregulation of DNA-PKcs mRNA was almost completely abolished by inhibitor treatment ( Figure 6B ). Subsequent ChIP analysis showed a functional interaction between c-Jun and c-Fos (members of the AP-1 complex) and the DNA-PKcs promoter ( Figure 6C-E) . Altogether, these data strongly suggest that the AP-1 mediates DNA-PKcs mRNA upregulation driven by HSF1. The relationship between HSF1 and DNA-PKcs was further investigated in human HCC specimens. A similar pattern to that described for p-DNA-PKcs was detected when assessing the total and activated/phosphorylated levels (Ser326) of HSF1. Indeed, total and activated/phosphorylated HSF1 protein levels as well as HSF1 mRNA and activity were progressively upregulated from nontumourous tissues to HCC when compared with normal livers, with the highest levels being detected in HCCP ( Figure 7A-D) . Furthermore, a significant, direct correlation was found between the levels of HSF1 activity and that of DNA-PKcs in the sample collection by Spearman's correlation test ( Figure 7E ). Also, an equivalent staining pattern for p-HSF1 and p-DNA-PKcs in normal livers, HCC and non-tumourous surrounding liver tissues was detected by immunohistochemistry ( Figure 8) . Finally, to delineate the importance of DNA-PKcs in HSF1-driven growth, we transiently overexpressed HSF1 gene in the SNU-423 cell line (exhibiting low basal levels of HSF1 mRNA) and evaluate the effects of DNA-PKcs silencing ( Supplementary  Figure 4) . Of note, suppression of DNA-PKcs by siRNA led to a remarkable decline in proliferation as well as increase in apoptosis and DNA damage in SNU-423 cells transfected with HSF1 ( Supplementary Figure 4) . 
DISCUSSION
Previous studies have shown that DNA-PKcs has either an oncogenic or tumour suppressive role in different tumour types (Hsu et al, 2012) . In the present investigation, we show that DNA-PKcs is aberrantly expressed and possesses oncogenic properties in human HCC. Indeed, we found a significant upregulation of DNA-PKcs and of its target H2AX, an earliest and specific marker of DSB (Garcia-Canton et al, 2012), in HCC when compared with normal livers and non-tumourous surrounding livers. These findings suggest that induction of DNA-PKcs is involved in liver malignant transformation. Moreover, a marked increase of DNA-PKcs levels was detected in HCCP when compared with HCCB, implying a role of DNA-PKcs also in HCC biological aggressiveness and patient's outcome. Accordingly, it has been previously shown that high levels of DNA-PKcs directly correlate with an unfavourable prognosis, tumour recurrence and resistance to radiotherapy in various cancer entities (Shintani et al, 2003; Hosoi et al, 2004; Tonotsuka et al, 2006; Parsons et al, 2008; Xing et al, 2008; Mukherjee et al, 2009 ). Therefore, the present data strongly support an important prognostic role of DNA-PKcs in human liver cancer.
Based on the present investigation, DNA-PKcs levels directly correlate with genomic instability and proliferation index, and inversely with the apoptotic index and patient's survival length, suggesting that DNA-PKcs contributes to hepatocarcinogenesis via multiple mechanisms. In accordance with the latter hypothesis, we found that DNA-PKcs silencing significantly reduced the growth and increased apoptosis in HCC cells. This disadvantageous effect on cell growth was strikingly augmented by the treatment with the DNA-damaging agent doxorubicin. Of note, the effects on in vitro growth following suppression of DNA-PKcs were much more pronounced in HCC than in non-transformed liver cell lines, implying an addiction of liver tumour cells to DNA-PKcs in order to proliferate and survive. Furthermore, a strong reduction of proliferation and induction of apoptosis accompanied the downregulation of DNA-PKcs in HCC cell lines irrespective of the status of the tumour suppressor gene p53 in these cells. This observation suggests that DNA-PKcs suppression might be universally detrimental for the growth of HCC cells. In addition, the different sensitivity exhibited by liver tumour and non-transformed cell lines toward depletion of DNA-PKcs, might have important therapeutic implications. Indeed, based on our findings in vitro, inhibiting DNA-PKcs activation could provide a multifaceted and effective chemotherapeutic strategy against liver cancer while sparing normal hepatocytes. 
